Sansure Biotech(SH:688289)2020-10-29 16:00Financial Performance - Net profit attributable to shareholders was CNY 2,012,815,337.70, representing a staggering increase of 10,702.39% year-on-year[17]. - Operating revenue for the first nine months was CNY 3,605,270,884.58, up 1,381.47% from the same period last year[17]. - The company reported a net profit increase, with a projected significant growth in net profit for the entire year compared to the previous year, driven by the surge in COVID-19 testing product sales[34]. - The company reported a total profit of ¥918,235,941.14 for Q3 2020, compared to ¥10,525,661.65 in Q3 2019, indicating a growth of approximately 8,694%[60]. - The company achieved a total revenue of ¥3,552,755,813.29 for the first three quarters of 2020, compared to ¥217,518,297.81 in the same period of 2019, reflecting an increase of approximately 1,532%[63]. Assets and Liabilities - Total assets reached CNY 5,157,991,030.86, an increase of 702.84% compared to the end of the previous year[17]. - Total current assets amounted to approximately CNY 4.86 billion, an increase from CNY 450.71 million year-over-year[40]. - Total liabilities amounted to CNY 718.44 million, an increase from CNY 84.99 million year-over-year[45]. - The total liabilities amounted to ¥703,769,811.10, with current liabilities at ¥682,081,628.18, indicating a strong liquidity position[51]. - The total assets amounted to ¥5,179,099,333.84, reflecting a robust asset base for the company[51]. Cash Flow - The net cash flow from operating activities was CNY 1,757,750,079.19, a significant recovery from a negative cash flow of CNY -49,774,717.91 in the previous year[17]. - Cash inflow from investment activities totaled CNY 737,483,322.82, significantly higher than CNY 113,995,008.53 in the previous year[75]. - The total cash inflow from operating activities was CNY 3,163,806,665.11, a significant increase from CNY 215,509,469.27 in the previous year[75]. - The net cash flow from operating activities was CNY 1,721,205,955.78, compared to a negative cash flow of CNY 51,255,726.69 in the same period last year[75]. - The company incurred a credit impairment loss of ¥-7,525,415.49 in Q3 2020, compared to a loss of ¥-32,010,656.29 in the previous period, showing an improvement in credit quality[66]. Shareholder Information - The company reported a total of 21,598 shareholders as of the end of the reporting period[20]. - The top shareholder, Dai Lizhong, holds 31.62% of the shares, totaling 126,488,642 shares[23]. - Shareholders' equity totaled CNY 4.44 billion, compared to CNY 557.48 million in the previous year[45]. Research and Development - Research and development expenses accounted for 1.75% of operating revenue, a decrease of 8.65 percentage points year-on-year[19]. - Research and development expenses for the first nine months were ¥62,987,590.54, up 148.94% from ¥25,301,961.45, indicating increased investment in R&D[32]. - Research and development expenses for Q3 2020 were ¥33,481,164.65, compared to ¥7,221,508.58 in Q3 2019, marking an increase of about 364%[56]. Future Outlook - The company anticipates continued growth in its COVID-19 testing products in Q4, alongside stable development in its existing businesses, positively impacting overall performance for 2020[34]. - The company has plans for market expansion and new product development in the upcoming quarters[41].